CYDY CytoDyn

CytoDyn to Deliver Presentation at Biotech Showcase Conference

CytoDyn to Deliver Presentation at Biotech Showcase Conference

VANCOUVER, Washington, Jan. 09, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that it will be presenting an update on the Company’s clinical development programs and objectives for leronlimab (PRO 140) during the Biotech Showcase on January 13, 2020 at 10:30 a.m. PT. More information regarding the conference can be found .  The Biotech Showcase is being held January 13 - 15, 2020 at the Hilton San Francisco Union Square in San Francisco, California. 

Nader Pourhassan, Ph.D., President and CEO of CytoDyn, will present an overview of the Company’s clinical programs and provide insights into his vision for CytoDyn in 2020, starting with its first BLA submission of leronlimab (PRO 140) and the future of leronlimab as a potential cancer therapy.  Dr. Pourhassan’s presentation is Monday, January 13 at 10:30 a.m. PT and a live webcast and replay of the presentation will be available  and on the Investors section of the Company’s website, .  This presentation will be followed by a breakout Q&A open to the conference participants. The webcast will be available approximately two hours after the webcast presentation ends and will be accessible for 90 days.

CONTACTS

Media:

Grace Fotiades

LifeSci Public Relations



(646) 876-502

Investors:

 

EN
09/01/2020

Underlying

CYDYCytoDyn

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CytoDyn

 PRESS RELEASE
Free
CYDY CYTODYN

CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Surviv...

CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference Leronlimab-mediated CCR5 blockade modulates T-Cell exhaustion pathways and PD-L1 Biology relevant to ICI response Durable Clinical Observations and Favorable Safety Profile Observed in Heavily Pretreated mTNBC Patients VANCOUVER, Washington, Feb. 20, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibod...

February 20, 2026 1 EN
 PRESS RELEASE
Free
CYDY CYTODYN

CytoDyn Announces Funding and Initiation of Expanded Access Program fo...

CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer VANCOUVER, Washington, Jan. 27, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including triple-negative breast cancer (TNBC) and metastatic colorectal cancer (mCRC), today announced that a compassionate benefactor has formally committed funding to support ...

January 27, 2026 1 EN
 PRESS RELEASE
Free
CYDY CYTODYN

December 2025 Letter to Shareholders

December 2025 Letter to Shareholders VANCOUVER, Washington, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As we close out the year and step with confidence and purpose into 2026, I want to extend my sincere appreciation for your support, patience, and continued belief in CytoDyn’s (the “Company”) mission. I will remember 2025 as the year in which we first presented our astonishing survival observations and compelling data on the emerging role of leronlimab in solid tumor oncology. This past year has been one of disciplined execution, operational rebuilding, and meaningful scient...

December 16, 2025 1 EN
 PRESS RELEASE
Free
CYDY CYTODYN

CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metast...

CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium Leronlimab treatment is associated with upregulation of PD-L1 in circulating tumor cells and cancer-associated macrophage-like cells Remarkably longer survival was observed in patients treated with leronlimab in combination with or followed by an immune checkpoint inhibitor VANCOUVER, Washington, Dec. 08, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, ...

December 8, 2025 1 EN
 PRESS RELEASE
Free
CYDY CYTODYN

CytoDyn Announces Resolution of Class Action Lawsuit

CytoDyn Announces Resolution of Class Action Lawsuit VANCOUVER, Washington, Dec. 01, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including metastatic triple-negative breast cancer (mTNBC) and colorectal cancer (mCRC), today announced that it has reached an agreement in principle to resolve the previously disclosed securities class action lawsuit that was initially fil...

December 1, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch